By Nascent Biotech Posted November 9, 2019 In Hugwil&Glassy Cancer 66 (003)2019-11-092019-11-09http://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttp://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.png200px200px 0 Hugwil&Glassy Cancer 66 (003) Recent PostsNascent Biotech Regains Worldwide Rights for PritumumabNBIO Link Report for May 10, 2023Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual MeetingA Letter to Nascent Biotech Shareholders, May 1, 2023
